Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study

View Full Paper
Ask AI
Bookmark
Share

Authors

GMGabriel N. MannisIAIrina AmitaiPSPaul J. Shami

Discussion

Loading...

Member takes

Overview

Phase 2 trial shows a 26% complete remission rate in relapsed NPM1m AML, suggesting revumenib may improve treatment options with existing therapies.

Key Points

  • Complete remission rate reached 26.0% among relapsed NPM1m AML patients treated with revumenib across various prior therapies.
  • Median duration of complete remission or partial recovery was 4.7 months, indicating potential durable responses in a challenging population.
  • Observational analysis of patients with relapsed NPM1m AML highlighted treatment outcomes by prior therapy type including venetoclax and hypomethylating agents.
  • Continued research is needed to further understand optimal treatment strategies and improve outcomes for this high-risk population.

Cite This Study

Mannis et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da73https://doi.org/10.1182/blood-2025-3418
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study2025 · 5 citations
  2. 2Early real-world experience with revumenib outside of a clinical trial setting: A single center retrospective review of efficacy and tolerability2025 · 2 citations
  3. 3The outcomes of patients who are relapsed or refractory to menin inhibitors is poor with a limited overall survival2025
  4. 4A Phase 1/2 study of the menin inhibitor revumenib with the celmod mezigdomide in relapsed/refractory KMT2A-rearanged, NPM1-mutant, and NUP98-rearranged acute leukemias2025
  5. 5Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-0072025 · 7 citations